North Immunology's ambitions to develop a long-acting antibody treatment for atopic dermatitis got a boost on Thursday in the form of a private placement and a reverse merger with Aethlon Medical. "This merger and significant financing is expected to provide the capital and public-company platform needed to advance NOR-101 into clinical development," said Jonathan Barr, CEO of North Immunology. NOR-101 is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both the ty

Preclinical data show AB-300, a non-hallucinogenic serotonin 2A receptor agonist, restores effort-based motivated behavior in a preclinical model of dopamine depletion Phase 1b clinical program supported by funding from The Michael J. Fox Foundation for Parkinson's Research; trial expected to begin in the second half of 2026 NEW YORK--(BUSINESS WIRE)-- #2A -- Palomar Labs ( formerly Negev Labs ), a venture studio that builds companies around neuropsychiatric drug development programs with prior

Paris, France, New York, USA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dr Grasso brings more than 28 years of public company, capital markets, and investment banking management experience Continues Cyllene Tx’s strategic business and clinical development growth in the US Paris, France and New York, USA, September 17, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-systemic, site-specific therapies for neurological disorders, today announced the appointment of Marc Grasso, MD,

— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh MTR. Inc. ("Curadh"), a company developing next-generation radiopharmaceuticals, announced the appointment of Dr. Alison Armour as Chief Medical Officer (CMO) of Alpha Fusion. The two companies also ann

CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from Sept

New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savings The breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how the

Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3 SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies for Parkinson’s disease (PD), today announced publicatio

New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction pro selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 years Across all four patient pro AUSTEDO ® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providers These findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while reinforcing

Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent applicati

HitGen Inc. (“HitGen”, SSE: 688222.SH) announced on September 17, 2026, that its wholly owned Hong Kong subsidiary, HitGen (HK) Ltd., has jointly invested in Connexus Therapeutics (“Connexus”) alongside OrbiMed Asia Partners, LAV, and Panku Capital Limited (a wholly owned subsidiary of Biokin Pharmaceutical). Connexus is a preclinical-stage biotechnology company focused on developing novel small molecule oncology therapeutics. HitGen (HK) Ltd. is the founding shareholder of Connexus. Under the a